NCT01347203View on ClinicalTrials.gov

A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Deep Vein Thrombosis Leg
Interventions
DRUG

DPOC-4088

A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)

DRUG

DPOC-4088

A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)

DRUG

DPOC-4088

A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)

DRUG

DPOC-4088

A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)

Trial Locations (1)

9000

Drug Reseach Unit Ghent, Ghent

Sponsors
All Listed Sponsors
lead

Diakron Pharmaceuticals

INDUSTRY

NCT01347203 - A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting | Biotech Hunter | Biotech Hunter